Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04047394
Other study ID # SYSS-SSS11-UND-?-02
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 22, 2019
Est. completion date December 30, 2022

Study information

Verified date July 2021
Source Shenyang Sunshine Pharmaceutical Co., LTD.
Contact Xianbo Li, MD
Phone 020-85959116
Email 285641182@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety, tolerability, PK and preliminary PD of SSS11 for injection in chinese healthy adult volunteers.


Description:

This is a phase I, open label, single-dose, dose-increasing study to assess the safety, tolerability and PK characteristics of healthy humans after injection of SSS11, provide a reference for subsequent clinical studies and give preliminary assessment of the immunogenicity and PD of SSS11.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date December 30, 2022
Est. primary completion date October 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Subjects in the age range between 18 and 45 years old (inclusive), male or female - In good health (no significant clinical symptoms or abnormal laboratory test results without clinical significance) - BMI within the range between 19 and 28 kg/m2 (inclusive) - Voluntarily sign the written informed consent - Be able to understand and comply with the requirements of clinical protocols, expected to complete the whole trial process - Subjects achieving full recovery if had the surgical treatment Exclusion Criteria: - Subjects cannot tolerate intravenous injection - Allergies or previous history of drug allergy, or allergic history of PEG-drugs, or previous history of allergies to two or more substances - Any abnormalities detected in three allergen tests (Special allergen screening - mixed mould, total IgE assay, special allergen screening - HX2) - Subjects having anti- PEG antibody - Taking any medicine before enrollment, and the regimen was less than five half-life periods or 4 weeks (Subject to the longest of the two) - Has a history of vaccination within 12 weeks before enrollment, or intend to receive vaccines during the study - Taking any other clinical trials within 12 weeks before enrollment,or have used similar drugs to the study drug - Having a history of blood donation within 12 weeks before enrollment - Having a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or abnormal G6PD detection - Having a history of catalase deficiency or evidence that individuals meet the criteria for catalase deficiency - Having a history of serious diseases, including but not limited to digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, neuropsychiatric system, blood system, immune system diseases and metabolic abnormalities - Having abnormalities and clinical significances in laboratory tests (blood routine, urine routine, blood biochemistry, etc.) and electrocardiogram findings within two weeks before enrollment - The HBsAg, anti-HIV, anti-HCV and treponema pallidum antibody were positive - The female within lactation, pregnancy, or having birth plan within 24 weeks - Blood pregnancy test was positive(female) - Male subjects who did not take effective contraception or their spouse plan to be born within 24 weeks - Disabled person in mental or law - Subjects having a history of alcohol abuse within 24 weeks prior to screening, equal to exceed 14 unit alcohol per week (1 unit = 12 ounces or 360 mL of beer, 1.5 ounces or 45 mL of 40% alcohol, 5 ounces or 150 mL of wine) - Smoking more than 5 cigarettes per day within 24 weeks before screening - Those who have had halo and fainting history - Drug abuse test or alcohol test was positive - Drinking more than 1L of tea, coffee and/or caffeinated beverages daily - Those who do not understand the content of informed consent and other those who do not meet the criteria for trial inclusion - Participants who researchers believe are not suitable (such as infirmity, etc.)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PEGylated recombinant candida urate oxidase
PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate

Locations

Country Name City State
China The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shenyang Sunshine Pharmaceutical Co., LTD.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events (AEs) Number of subjects with Adverse events (AEs) From the day signing in informed consent form to the day 56 post-dose
Primary DLT Dose-LimitingToxicity of SSS11 From day 1 to day 56
Primary Cmax Maximum plasma concentration (Cmax) of single dose SSS11 From beginning of drug administration to day 56
Primary Tmax Peak plasma time [tmax] of single dose SSS11 From beginning of drug administration to day 56
Primary AUC Area under the plasma concentration versus time curve (AUC) of single dose SSS11 From beginning of drug administration to day 56
Secondary Anti-urate oxidase antibody The immunogenicity of SSS11 was assessed in subjects by detecting the anti-urate oxidase antibody. From pre-dose on week 2 up to week 1, 2, 4 and 7 post-dose.
Secondary Uric acid levels in blood This parameter was used to evaluate the PD of SSS11 in healthy humans. From beginning of drug administration to day 56
Secondary Uric acid levels in urine This parameter was used to evaluate the PD of SSS11 in healthy humans. From beginning of drug administration to day 6
See also
  Status Clinical Trial Phase
Completed NCT04060173 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 Phase 1
Not yet recruiting NCT06187519 - UR+AIMS Gout Wearable Skin Uric Acid Monitor Study N/A
Completed NCT03635957 - Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout Phase 4
Completed NCT04966325 - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects Early Phase 1
Completed NCT03015948 - A Single Dose Study of SHR4640 in Healthy Male Volunteers Phase 1
Completed NCT02855437 - Novel Methods for Ascertainment of Gout Flares -A Pilot Study N/A
Active, not recruiting NCT02702375 - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases N/A
Completed NCT01407874 - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency Phase 2
Completed NCT00985127 - Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout Phase 2
Completed NCT00995618 - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia Phase 2
Terminated NCT04987294 - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease Phase 2
Completed NCT03291782 - D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers Phase 1
Recruiting NCT03388515 - A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects. Phase 1
Completed NCT06189404 - Effect of Tigulixostat on the Pharmacokinetics of Theophylline Phase 1
Enrolling by invitation NCT03336203 - The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Phase 4
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Not yet recruiting NCT05507723 - Tight Control of Gouty Arthritis Compared to Usual Care N/A
Recruiting NCT06056570 - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia Phase 1/Phase 2
Completed NCT02557126 - Study of URC102 to Assess the Safety and Efficacy in Gout Patients Phase 2
Completed NCT02246673 - RDEA3170 and Febuxostat Combination Study in Gout Subjects Phase 2